Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 24Colorectal Neoplasms 5Squamous Cell Carcinoma of Head and Neck 2Stomach Neoplasms 1Solid Tumors 1Solid Tumor, Adult 1Salivary Gland Neoplasms 1RAS/BRAF Wild-type Advanced Colorectal Cancer Patients 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Metastatic Non-small Cell Lung Cancers 1Lung Neoplasms 1Locally Recurrent Skin Squamous Cell Carcinoma 1Head and Neck Neoplasms 1Glioblastoma 1Esophageal Neoplasms 1Carcinoma, Hepatocellular 1Carcinoma, Adenoid Cystic 1Breast Neoplasms 1

Interventions

Paclitaxel 15atezolizumab 11Gemcitabine 11Carboplatin 9pembrolizumab 8Docetaxel 8Bevacizumab 8Irinotecan 7Injections 6Cetuximab 6Capecitabine 6Sunitinib 5Leucovorin 5Fluorouracil 5Cyclophosphamide 5tocilizumab 4pazopanib 4olaparib 4navitoclax 4liposomal doxorubicin 4Topotecan 4Oxaliplatin 4Nivolumab 4Erlotinib Hydrochloride 4temsirolimus 3spartalizumab 3lenvatinib 3fludarabine 3cobimetinib 3Cisplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Tumors × amivantamab × Clear all
NCT06816992 2026-04-24

ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC

ORIC Pharmaceuticals

Phase 1 Recruiting
76 enrolled
Other solid neoplasmThoracic

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡